ADMA Biologics (ADMA) Competitors

ACADIA Pharmaceuticals (NASDAQ:ACAD) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

Which has more risk and volatility, ACAD or ADMA?

ACADIA Pharmaceuticals has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.

Which has preferable valuation and earnings, ACAD or ADMA?

ACADIA Pharmaceuticals has higher revenue and earnings than ADMA Biologics. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$957.80M	4.18	$226.45M	$1.33	17.82
ADMA Biologics	$474.17M	7.94	$197.67M	$0.86	18.34

Does the media prefer ACAD or ADMA?

In the previous week, ACADIA Pharmaceuticals had 21 more articles in the media than ADMA Biologics. MarketBeat recorded 24 mentions for ACADIA Pharmaceuticals and 3 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.48 beat ACADIA Pharmaceuticals' score of 1.02 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	12 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate ACAD or ADMA?

ACADIA Pharmaceuticals currently has a consensus target price of $29.65, indicating a potential upside of 25.08%. ADMA Biologics has a consensus target price of $27.67, indicating a potential upside of 75.38%. Given ADMA Biologics' stronger consensus rating and higher probable upside, analysts clearly believe ADMA Biologics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.63
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Is ACAD or ADMA more profitable?

ADMA Biologics has a net margin of 44.06% compared to ACADIA Pharmaceuticals' net margin of 21.80%. ADMA Biologics' return on equity of 41.01% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	21.80%	14.69%	9.41%
ADMA Biologics	44.06%	41.01%	28.47%

Do insiders and institutionals have more ownership in ACAD or ADMA?

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 26.5% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

ACADIA Pharmaceuticals and ADMA Biologics tied by winning 8 of the 16 factors compared between the two stocks.